US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Rafael Holdings, Inc. Class B Common Stock (NY:RFL)

1.540 +0.040 (+2.67%)
Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rafael Holdings, Inc. Class B Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing ↗
Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company... 
Via MarketBeat
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Wednesday? ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Thursday's session. ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
From Rafael Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >